A Critical Nexus:The Clinician and the Researcher.
14 July 2020
As clinician researchers, with busy clinical loads, our greatest challenge is ﬁnding time to engage deeply in the science. But it is necessary to deliver on our research goals.
The nexus between the clinician and the researcher is critical and underpins successful cancer research.
Embedded in every academic clinical cancer service there needs to be a vibrant program of research, which includes basic and translational research. Similarly, embedded in every cancer-related research laboratory, strong links to clinicians at the front line are essential. By working together, clinicians and scientists can gain insights beyond those easily achieved individually.
The clinician and scientist approach the cancer challenge from differing perspectives. Clinicians have a global perspective of the disease enabling them to identify what needs to change for maximal impact. Scientists tend to have a meticulous understanding of speciﬁc steps within complex biological systems - breaking the big picture into smaller parts, thus identifying opportunities for manipulation. Neither can successfully achieve the goal without the other.
This symbiotic relationship is well illustrated by modern cancer immunotherapy. For decades, clinicians recognised that immune manifestations correlated with good outcomes, but it was not until James Allison and Tasuko Honjo identiﬁed critical checkpoints in immune regulation that the opportunity to harness the immune system against cancer was realised. Now, checkpoint inhibitor drug therapies have transformed the cancer ﬁeld, highlighting what can be achieved when clinicians and scientists build upon their respective insights.
Article by Professor Georgina Long AO and Profesor Richard Scolyer, Melanoma Institute Australia and University of Sydney.
Read the full article Voices:Translating Basic Cancer Discoveries to the Clinic in Cancer Cell 37 here
Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.
Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.
We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.
Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.
An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.
Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.
Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.
It’s time again to say thank you to our amazing community fundraisers!
Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.
MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.
Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.
MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.
Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.
It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.